Relieves osteoarthritis and rheumatoid arthritis. ANDA 91083, held by Watson Labs. Nabumetone.
As of Nov 15, 2026, ANDA 91083 (Nabumetone), held by Watson Labs, was first approved by FDA on Jun 13, 2011, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2011 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 24, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 13, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters